TY - JOUR
T1 - Non-erythropoiesis-stimulating agent, non-iron therapies for the management of anaemia
T2 - protocol for a scoping review
AU - Devlin, Paula
AU - Davies, Amelia
AU - Dugan, Cory
AU - Richards, Toby
AU - Miles, Lachlan F.
N1 - Funding Information:
Competing interests All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/disclosure-of-interest/ and declare the Division of Surgery of the University of Western Australia is the sponsor, with overall control of the data. TR reports grants from the National Institute for Health Research (UK), National Health and Medical Research Council (Australia); grants, personal fees and non-financial support from Pharmocosmos Therapeutics; grants, personal fees and non-financial support from Vifor Pharma Pty; grants from the Medical Research Future Fund (Australia); grants from the Future Health Research and Innovation Fund (Western Australia); grants and personal fees from Pfizer Pty (Australia); and personal fees from BioAge Labs, outside the submitted work. TR is a regular speaker at national and international conferences on anaemia, blood transfusion, wound healing and vascular disease, for which he has received expenses for travel, accommodation and sundries; has worked with several agencies promoting meetings or healthcare; is a director of The Iron Clinic, director of Veincare London and Vein Care WA; and is the vascular lead for 18-Week Wait. LFM reports grants from Vifor Pharma Pty, the Australian and New Zealand College of Anaesthetists, the Victorian Department of Health, the Epworth Medical foundation and the Austin Medical Research foundation, outside the submitted work; has a leadership or fiduciary role with the National Medical Advisory Committee, Red Cross Lifeblood, Australia and Blood Matters Advisory Committee, Department of Health and Victorian State Government. PD, AD and CD declare no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years and no other relationships or activities that could appear to have influenced the submitted work.
Publisher Copyright:
©
PY - 2022/4
Y1 - 2022/4
N2 - Introduction Preoperative anaemia is associated with poor postoperative outcomes and is the strongest predictor of allogenic blood transfusion, which contributes further to patient morbidity. Emphasis has been placed on correcting anaemia prior to surgery to mitigate these outcomes. Conflicting evidence exists regarding the benefit of currently recommended interventions. With greater understanding of iron haemostasis and erythropoiesis, novel therapies have been identified. These are at varying stages of development with some demonstrating promising results in patients with chronic kidney disease. It is not known how these agents have been studied outside this population, particularly in the perioperative context. To address this, we will conduct a scoping review of the published literature to chart the evidence. Methods and analysis The scoping review will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews framework. The electronic database search will include Scopus, MEDLINE (Ovid) and Excerpta Medica database (Ovid), with no language restrictions, and will include all publications since 1 January 2010. This review will have three objectives: (1) to describe the mechanisms of action for novel agents, (2) to describe the level of evidence and stage of development of novel agents in a perioperative setting, and (3) to determine the potential agents suitable for prospective controlled trials in a preoperative or postoperative patient cohort and aiming to improve patient-centred outcomes. The review process will involve two reviewers with a third reviewer resolving disagreements. Data will be extracted and organised with subsequent analysis. Ethics and dissemination This scoping review does not require research ethics approval. The results will be published in a peer-reviewed journal and inform the development of future prospective trials based on established evidence from potential therapeutic agents. Trial registration number This protocol has been registered prospectively on the Open Science Framework registry (DOI:10.17605/OSF.IO/SM3UH, https://osf.io/sm3uh/?view_only=39876ccf7a4348dfbd566535b957a7db).Cite Now
AB - Introduction Preoperative anaemia is associated with poor postoperative outcomes and is the strongest predictor of allogenic blood transfusion, which contributes further to patient morbidity. Emphasis has been placed on correcting anaemia prior to surgery to mitigate these outcomes. Conflicting evidence exists regarding the benefit of currently recommended interventions. With greater understanding of iron haemostasis and erythropoiesis, novel therapies have been identified. These are at varying stages of development with some demonstrating promising results in patients with chronic kidney disease. It is not known how these agents have been studied outside this population, particularly in the perioperative context. To address this, we will conduct a scoping review of the published literature to chart the evidence. Methods and analysis The scoping review will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews framework. The electronic database search will include Scopus, MEDLINE (Ovid) and Excerpta Medica database (Ovid), with no language restrictions, and will include all publications since 1 January 2010. This review will have three objectives: (1) to describe the mechanisms of action for novel agents, (2) to describe the level of evidence and stage of development of novel agents in a perioperative setting, and (3) to determine the potential agents suitable for prospective controlled trials in a preoperative or postoperative patient cohort and aiming to improve patient-centred outcomes. The review process will involve two reviewers with a third reviewer resolving disagreements. Data will be extracted and organised with subsequent analysis. Ethics and dissemination This scoping review does not require research ethics approval. The results will be published in a peer-reviewed journal and inform the development of future prospective trials based on established evidence from potential therapeutic agents. Trial registration number This protocol has been registered prospectively on the Open Science Framework registry (DOI:10.17605/OSF.IO/SM3UH, https://osf.io/sm3uh/?view_only=39876ccf7a4348dfbd566535b957a7db).Cite Now
KW - Adult anaesthesia
KW - Anaemia
KW - Blood bank & transfusion medicine
KW - SURGERY
UR - http://www.scopus.com/inward/record.url?scp=85128042778&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2021-059059
DO - 10.1136/bmjopen-2021-059059
M3 - Review Article
C2 - 35410937
AN - SCOPUS:85128042778
SN - 2044-6055
VL - 12
JO - BMJ Open
JF - BMJ Open
IS - 4
M1 - 059059
ER -